Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 12 of 12 for “"mCRPC"”.
-
CRISPR/Cas9 screenings and in silico investigations nominate low-frequency alterations in DNA repair genes as biomarkers for castration-resistant prostate cancers.
… metastatic castration-resistant prostate cancer (mCRPC) patients characterized by defects in homologous recombination repair genes. Clinical trials results suggest that further improvements are possible, for instance in terms of patients’ enrolment criteria. Only 50% of BRCA1/2-deficient patients …
-
Targeting the Tumor Stroma Using a Monoclonal Antibody Platform Technology
… metastatic castration resistant prostate cancer (mCRPC) are left with few therapeutic options. Current second line therapies only provide a small survival benefit and there is a critical unmet need for new and innovative approaches to treat mCRPC. Imaging is a crucial aspect of mCRPC clinical …
-
Role of the extracellular matrix-integrin interaction in enzalutamide resistance of bone metastatic castration-resistant prostate cancer
… castration-resistant prostate cancer (bone mCRPC) is the most prevalent type of prostate cancer metastasis, accounting for 90% of all metastasis incidence. Its resistance to androgen-deprivation therapy (ADT). Enzalutamide (Enz) is a second-generation androgen-receptor (AR) antagonist, …
-
Decoding the RNA cargo of plasma-derived extracellular vesicles in metastatic castration-resistant prostate cancer
… metastatic castration-resistant prostate cancer (mCRPC) patients, treated with Enzalutamide in a chemo-naïve setting. Specifically, it incorporates EV physical characterization, EV-RNA and matched cfDNA genomics. The use of total RNA sequencing (RNA-seq) enabled the detection of both coding and …
-
Targeting LEDGF/p75 to Sensitize Chemoresistant Prostate Cancer Cells to Taxanes
… metastatic castration resistant prostate cancer (mCRPC) cells selected for resistance to the taxane drug docetaxel (DTX). These cells also showed resistance to the taxanes cabazitaxel (CBZ) and paclitaxel (PTX), but not to the classical inducer of apoptosis TRAIL. Silencing LEDGF/p75 effectively …
-
Radiobiological mechanisms and novel imaging biomarkers in metastatic prostate cancer treated with radium-223
… present in 90% of patients with metastatic CRPC (mCRPC). The use of alpha (α)-particle radionuclide emitters for the treatment of metastatic bone disease is an active area of research in targeted radionuclide therapies, in particular radium-223.<br/><br/>Radium-223 is a targeted α-therapy, which …
-
Chemoligand therapy for metastatic castration-resistant prostate cancer
… metastatic castration-resistant prostate cancer (mCRPC) has moderate to high nonphysiological levels of a transmembrane protein known as prostate-specific membrane antigen (PSMA) and creates opportunities for precision medicine approaches. Using PSMA as a mechanism of disease selection, I …
-
Augmenting Natural Killer cell antibody binding to enhance ovarian and prostate tumor cell killing via ADCC
… metastatic castration resistant prostate cancer (mCRPC) are a leading cause of cancer-related deaths worldwide. Natural killer (NK) cells are cytotoxic lymphocytes that rapidly kill tumor cells via antibody-dependent cell-mediated cytotoxicity (ADCC). ADCC is exclusively mediated by the IgG Fcγ …
-
The role of BET proteins in castration-resistant prostate cancer dissemination
… metastatic castration-resistant prostate cancer (mCRPC). Here, we examined prostate cancer cell lines that model common CRPC subtypes, each with different AR composition, and focused on novel regulators of tumor progression, the Bromodomain and ExtraTerminal (BET – BRD2, BRD3 and BRD4) family of …
-
An innate immune response to DNA damage in prostate cancer
… research has shown that up to 25% of men with mCRPC harbour mutations in DNA Repair genes BRCA1/ BRCA2 and ATM. This group has previously identified a molecular subtype in solid tumors characterised by STING mediated immune signalling due to abnormal DNA as a result of loss of DNA repair …
-
Investigation of the role of Col4a1 and Itga11 in enzalutamide resistance of prostate cancer cells
… morbidity and mortality. Metastatic CRPC (mCRPC) is currently incurable and accounts for over 90% of PCa-related deaths. Tumour-associated macrophages (TAMs) can promote ADT resistance in bone metastasis, but the mechanism is yet unknown. Recent studies in our lab have identified that …
-
ROLE OF HIGH DENSITY LIPOPROTEINS AGAINST PROSTATE CANCER
… of patient-derived organoids, derived from mCRPC and NE-CRPC biopsies. Gene and protein expression analyses revealed that PCa cells overexpress LDL-R and LRP1, suggesting a reliance on extracellular cholesterol uptake rather than de novo synthesis. This is supported by functional data …